Excalibur Group

Excalibur Group is a prominent UK-based life sciences organization founded and led by Professor Sir Christopher Evans, a leading figure in the European biotechnology sector. The group encompasses several entities, most notably Excalibur Healthcare Services and Excalibur Medicines, which together provide a broad spectrum of healthcare solutions ranging from diagnostic testing and medical devices to drug development. A key asset in their therapeutic pipeline is AZD1656, a small molecule glucokinase activator being investigated for its potential to modulate the immune response in COVID-19 patients and for treating diabetes. The company played a significant role during the COVID-19 pandemic by supplying millions of rapid diagnostic tests and establishing high-capacity laboratory facilities. Headquartered in London, Excalibur Group continues to leverage its extensive network and expertise to advance innovative medical technologies and therapies.